Golden
Kala Pharmaceuticals

Kala Pharmaceuticals

A biopharmaceutical company that develops nanotherapeutic treatments for ocular diseases and other eye related conditions

All edits

Edits on 12 Jun 2019
Golden AI
Golden AI edited on 12 Jun 2019 10:10 pm
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 12 Jun 2019 9:54 pm
Edits made to:
Infobox (+1 properties)
Golden AI
Golden AI edited on 12 Jun 2019 9:37 pm
Edits made to:
Infobox (+1 properties)
Edits on 29 May 2019
Golden AI
Golden AI edited on 29 May 2019 2:14 pm
Edits made to:
Infobox (+1 properties)

Infobox

Founder
Edits on 26 Apr 2019
Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 26 Apr 2019 6:10 pm
Edits made to:
Article (+13/-13 characters)

Article

On April 23, 2014 Kala Pharmaceuticals completed their series B funding round with $22.5 million in funding from Ysios CapitalYsios Capital (lead investor), Third Rock Ventures, Polaris Partners, Lux Capital, Crown Venture Fund, and AbbVie Biotech Ventures. 

Edits on 25 Apr 2019
Golden AI
Golden AI edited on 25 Apr 2019 12:52 am
Edits made to:
Infobox (+2 properties)

Infobox

Edits on 29 Mar 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 29 Mar 2019 4:38 pm
Edits made to:
Article (+7/-7 characters)

Article

On February 28, 2013 Kala Pharmaceuticals completed their series A funding round with $11.5 million in funding from Crown Venture Fund (lead investor), Crown family of ChicagoChicago, Lux Capital Management, Polaris Venture Partners, and Third Rock Ventures. 

Dawson Sewell
Dawson Sewell edited on 29 Mar 2019 2:53 pm
Edits made to:
Infobox (+5 properties)
Timeline (+3 events) (+817 characters)
Article (+959 characters)
Further reading (+4 cells) (+292 characters)
Related Topics (+1 topics)

Article

Kala Pharmaceuticals is a biotechnology company headquartered in Waltham, Massachusetts and was founded in 200 by Justin Hanes and Robert Langer.



The name Kala, from Kala Pharmaceuticals, comes from the Kalalau trail in Kauai, Hawaii, known for its strenuous path and difficult terrain but also for its beauty. The company is developing and commercializing therapeutics using their proprietary mucus-penetrating particle (MPP) technology with an initial focus on eye disease. MPPs are selectively sized with proprietary coatings, two characteristics the company believes enable even distribution of drug particles on mucosal surfaces and increase drug delivery to target tissues. 

...

Funding

Series A

On February 28, 2013 Kala Pharmaceuticals completed their series A funding round with $11.5 million in funding from Crown Venture Fund (lead investor), Crown family of Chicago, Lux Capital Management, Polaris Venture Partners, and Third Rock Ventures. 

Series B

On April 23, 2014 Kala Pharmaceuticals completed their series B funding round with $22.5 million in funding from Ysios Capital (lead investor), Third Rock Ventures, Polaris Partners, Lux Capital, Crown Venture Fund, and AbbVie Biotech Ventures. 

Series C

On April 13, 2016 Kala Pharmaceuticals completed their series C funding round with $68 million in funding from Longitude Capital (lead investor), Wellington Management, Vivo Capital, RA Capital Management, Polaris Partners, Lux Capital, and CAM Capital. 

Further reading

Title
Author
Link
Type

Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration

Business Wire

Web

Infobox

Related Topics

Timeline

April 13, 2016

Series C funding round

On April 13, 2016 Kala Pharmaceuticals completed their series C funding round with $68 million in funding from Longitude Capital (lead investor), Wellington Management, Vivo Capital, RA Capital Management, Polaris Partners, Lux Capital, and CAM Capital. 

April 23, 2014

Series B funding round

On April 23, 2014 Kala Pharmaceuticals completed their series B funding round with $22.5 million in funding from Ysios Capital (lead investor), Third Rock Ventures, Polaris Partners, Lux Capital, Crown Venture Fund, and AbbVie Biotech Ventures. 

February 28, 2013

Series A funding round

On February 28, 2013 Kala Pharmaceuticals completed their series A funding round with $11.5 million in funding from Crown Venture Fund (lead investor), Crown family of Chicago, Lux Capital Management, Polaris Venture Partners, and Third Rock Ventures. 

Edits on 23 Mar 2019
Neelam Jhaveri
Neelam Jhaveri approved a suggestion from Golden's AI on 23 Mar 2019 12:30 pm
Edits made to:
Article (+6/-6 characters)

Article

The name Kala comes from the Kalalau trail in Kauai, HawaiiHawaii, known for its strenuous path and difficult terrain but also for its beauty. The company is developing and commercializing therapeutics using their proprietary mucus-penetrating particle (MPP) technology with an initial focus on eye disease. MPPs are selectively sized with proprietary coatings, two characteristics the company believes enable even distribution of drug particles on mucosal surfaces and increase drug delivery to target tissues. 

Edits on 20 Mar 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 20 Mar 2019 12:50 am
Edits made to:
Article (+5/-5 characters)

Article

The name Kala comes from the Kalalau trail in KauaiKauai, Hawaii, known for its strenuous path and difficult terrain but also for its beauty. The company is developing and commercializing therapeutics using their proprietary mucus-penetrating particle (MPP) technology with an initial focus on eye disease. MPPs are selectively sized with proprietary coatings, two characteristics the company believes enable even distribution of drug particles on mucosal surfaces and increase drug delivery to target tissues. 

Edits on 17 Mar 2019
Meredith Hanel
Meredith Hanel edited on 17 Mar 2019 1:46 pm
Edits made to:
Description (+16 characters)
Topic thumbnail

Kala Pharmaceuticals

A biopharmaceutical company that develops nanotherapeutic treatments for ocular diseases and other eye related conditions

Meredith Hanel
Meredith Hanel edited on 16 Mar 2019 10:43 pm
Edits made to:
Description (+28/-5 characters)
Article (+1162 characters)
Categories (+1/-2 topics)
Related Topics (+1 topics)
Topic thumbnail

Kala Pharmaceuticals

A biopharmaceutical company that develops treatments for ocular diseases and other eye related casesconditions

Article

The name Kala comes from the Kalalau trail in Kauai, Hawaii, known for its strenuous path and difficult terrain but also for its beauty. The company is developing and commercializing therapeutics using their proprietary mucus-penetrating particle (MPP) technology with an initial focus on eye disease. MPPs are selectively sized with proprietary coatings, two characteristics the company believes enable even distribution of drug particles on mucosal surfaces and increase drug delivery to target tissues. 



Kala created nanosuspensions of loteprednol etabonate (LE), a corticosteroid, with their MPP technology to generate two lead product candidates, INVELTYS (PI-121 1.0%) and KPI-121 0.25%. IVELTYS is for treating inflammation and pain after ocular surgery and KPI-121 0.25% is for temporary relief of dry eye disease signs and symptoms. 

...

Iveltys which won FDA approval in 2018, is a new formulation of a topical steroid from Bausch Health which did not use nanoparticle technology. Iveltys is claimed to have better efficacy, safety and convenience for patients. Preliminary results from a Phase 3 study on KPI-121 are expected to be available in late 2019.

Categories

Related Topics

Edits on 21 Jan 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan 2019 10:10 pm
Edits made to:
Infobox (+1/-1 properties)

Infobox

Edits on 10 Jan 2019
Golden AI
Golden AI edited on 10 Jan 2019 9:43 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 12 Dec 2018
Golden AI"Import data"
Golden AI edited on 12 Dec 2018 1:12 am
Edits made to:
Infobox (+3 properties)
Edits on 18 Sep 2018
Golden AI"Import data from spreadsheet"
Golden AI edited on 18 Sep 2018 7:59 pm
Edits made to:
Categories (+1 topics)

Categories

Edits on 19 Jul 2018
Golden AI"Update locations in infobox"
Golden AI edited on 19 Jul 2018 8:53 pm

Infobox

Edits on 29 Jun 2018
Golden AI"Update infobox"
Golden AI edited on 29 Jun 2018 5:50 pm

Infobox

Edits on 18 Jun 2018
Golden AI"Updating description"
Golden AI edited on 18 Jun 2018 10:52 pm
Edits made to:
Description (+82/-21 characters)
Topic thumbnail

Kala Pharmaceuticals

Biotechnology company

A company that develops treatments for ocular diseases and other eye related cases

Edits on 29 May 2018
Golden AI"Initial topic creation"
Golden AI created this topic on 29 May 2018 9:30 pm
Edits made to:
Description (+21 characters)
People (+2 cells) (+16 characters)
Categories (+1 topics)
Topic thumbnail

 Kala Pharmaceuticals

Biotechnology company

People

Name
Role
Related Golden topics

Rob Paull

Founder



Categories

No more activity to show.